methods: Nuclear Magnetic Resonance spectroscopy analysis was performed on blood samples collected at baseline and after dosing in three double-blind, placebo (PBO)-controlled, randomized studies. In Study #1, 67 HC subjects with LDL-C ≥ 130 mg/dL were treated with 0.25, 0.5, 1 and 1.5 mg/kg RN316 monotherapy intravenously (IV) or PBO every week for 4 weeks. In Study #2, 90 HC subjects with LDL-C ≥ 100 mg/dL on statins were treated with 0.25, 1, 3 & 6 mg/kg RN316 IV or PBO every 4 weeks. In Study #3, 45 HC subjects with LDL-C ≥ 80 mg/dL on statins were treated with 1 or 3 mg/kg RN316 IV or PBO every 4 weeks. Lipoprotein particle concentrations were derived for spectrally distinct VLDL, LDL and HDL subclasses. Mass-weight average particle diameters were calculated. conclusions: RN316 treatments led to significant reductions in VLDL, LDL and small LDL particle concentrations, small increases in HDL particle concentrations and small increases in particle sizes. The effects of RN316 are consistent with its mechanism of blocking PCSK9-mediated downregulation of LDLR.
